

News Release



January 28, 2026
JCR Pharmaceuticals Co., Ltd.

Recognition of Subsidy Income as Extraordinary Income

Hyogo, Japan – January 28, 2026 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the recognition of subsidy income as special income for Q3 FY2025 (October 1, 2025 – December 31, 2025), as outlined below.

1. Details of Extraordinary Income (Subsidy Income)

A government subsidy related to the construction of the Kobe Science Park Center (API plant) was finalized in the third quarter. As a result, JCR recognized 1,882 million yen as extraordinary income. This amount represents the net portion of the subsidy after deducting the amount applied to tax purpose reduction entry and the unused portion to be refunded.

2. Impact on Financial Results

For the impact on financial results, please refer to today’s “Financial Results for the Nine Months ended December 31, 2025 (FY2025) (Japanese standard).”

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###